RecruitingNot ApplicableNCT06980103

Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer

Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer: The Radiance Trial

Sponsor

Georgetown University

Enrollment

408 participants

Start Date

Aug 6, 2025

Study Type

INTERVENTIONAL

Conditions

Thyroid Cancer

Summary

The goal of this study is to learn if a decision aid (DA) website helps people with thyroid cancer make informed decisions about radioactive iodine (RAI) treatment. The main questions it aims to answer are: - Does the decision aid help participants understand the risks and benefits of RAI treatment? - Does it help participants make choices that reflect what matters most to them? - How does the decision aid compare to usual care in supporting patients through this decision? Participants who have been recently diagnosed with intermediate-risk differentiated thyroid cancer (DTC) will be randomly assigned to one of two groups. One group will receive a special decision aid website. This site includes detailed information about RAI, short videos, drop-down menus with extra details, exercises to help clarify values, and tools to help patients prepare questions for their doctor. The other group will receive the American Cancer Society (ACS) website. This site gives basic information about RAI but does not include interactive tools and is not specific to intermediate-risk thyroid cancer. Follow up surveys will be sent to the participants periodically, first at the start of the study, and again at 1 week, 4 weeks, and 6 months later. Researchers will compare how the two groups differ in making informed decisions. The decision aid is meant to support, not replace, a conversation with the medical team. Doctor recommendations remain an important part of treatment decisions.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is designed to help people with intermediate-risk thyroid cancer make a more informed decision about whether to receive radioactive iodine (RAI) treatment after surgery. RAI is sometimes used to destroy remaining thyroid tissue, but for intermediate-risk patients, whether it helps is often unclear. This trial tests whether a special decision-support tool helps patients feel more confident and clear about their choice. **You may be eligible if...** - You are 18 or older - You were recently diagnosed (within the last 6 months) with intermediate-risk differentiated thyroid cancer - You are currently deciding whether to pursue radioactive iodine treatment - You are mentally able to read and understand the information provided **You may NOT be eligible if...** - You were diagnosed with low-risk or high-risk thyroid cancer (not intermediate-risk) - You have already received radioactive iodine treatment in the past - You are pregnant, breastfeeding, or have a medical reason that makes RAI unsuitable (such as very low white blood cell counts) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALDecision Aid

The study intervention is a web-based decision aid (DA) developed by the study team. The Radioactive Iodine Decisions decision aid is designed as an educational tool to help patients have information about Radioactive Iodine and encourage them to talk with their medical team about this treatment decision.

BEHAVIORALUsual Care

Patients randomized in the Usual Care Condition arm will receive a link for the American Cancer Society website on Radioactive Iodine (Radioiodine) Therapy for Thyroid Cancer as our comparison.